<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Inhibrx Inc — News on 6ix</title>
<link>https://6ix.com/company/inhibrx-inc</link>
<description>Latest news and press releases for Inhibrx Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 20:05:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/inhibrx-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683583b378dffbe2df0fccd9.webp</url>
<title>Inhibrx Inc</title>
<link>https://6ix.com/company/inhibrx-inc</link>
</image>
<item>
<title>Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-provides-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-provides-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer</guid>
<pubDate>Tue, 21 Apr 2026 20:05:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced updated interim data from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC).</description>
</item>
<item>
<title>Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-ozekibart-inbrx-109-in-late-line-colorectal-cancer</guid>
<pubDate>Mon, 20 Apr 2026 21:03:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Tuesday, April 21, 2026 at 1:30 p.m. Pacific Time to provide a clinical update from its Phase 1/2 study evaluating ozekibart (INBRX-109) in combination with FOLFIRI in patients with locally advanced or metastatic, unresectable colorectal cancer (CRC).</description>
</item>
<item>
<title>Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-fourth-quarter-and-fiscal-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-fourth-quarter-and-fiscal-year-2025-financial-results</guid>
<pubDate>Thu, 19 Mar 2026 20:00:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials.</description>
</item>
<item>
<title>Inhibrx Announces Participation in Upcoming Scientific Conference</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-announces-participation-in-upcoming-scientific-conference</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-announces-participation-in-upcoming-scientific-conference</guid>
<pubDate>Mon, 02 Mar 2026 21:00:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference:</description>
</item>
<item>
<title>Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-biosciences-provides-progress-updates-220000433</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-biosciences-provides-progress-updates-220000433</guid>
<pubDate>Tue, 16 Dec 2025 22:00:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology today announced an update on the INBRX-106 Phase 2/3 clinical trial in combination with Keytruda® (pembrolizumab) as a first-line treatment for patients with locally advanced unresectable or metastatic head and neck squamous cell carcinoma (HNSCC) and the Phase 1/2 trial evaluating patients with checkpoint inhibitor refractory or relaps</description>
</item>
<item>
<title>Inhibrx Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-third-quarter-2025-110000277</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-third-quarter-2025-110000277</guid>
<pubDate>Fri, 14 Nov 2025 11:00:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials.</description>
</item>
<item>
<title>Inhibrx Announces Participation in Upcoming Scientific Conferences</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-announces-participation-upcoming-scientific-210100480</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-announces-participation-upcoming-scientific-210100480</guid>
<pubDate>Tue, 04 Nov 2025 21:01:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:</description>
</item>
<item>
<title>Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-biosciences-reports-positive-topline-200500734</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-biosciences-reports-positive-topline-200500734</guid>
<pubDate>Thu, 23 Oct 2025 20:05:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosarcoma. The Company also provided updates on the ongoing expansion cohorts investigating ozekibar</description>
</item>
<item>
<title>Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-host-webcast-presentation-topline-200100710</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-host-webcast-presentation-topline-200100710</guid>
<pubDate>Wed, 22 Oct 2025 20:01:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced that it will host a live webcast presentation on Thursday, October 23, 2025 at 1:30 p.m. Pacific Time to provide topline results from the registrational ChonDRAgon study investigating ozekibart (INBRX-109) as a single agent versus placebo in patients with advanced or metastatic, unresectable chondrosar</description>
</item>
<item>
<title>Inhibrx Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-second-quarter-2025-200500652</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-second-quarter-2025-200500652</guid>
<pubDate>Wed, 13 Aug 2025 20:05:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spi</description>
</item>
<item>
<title>Inhibrx Reports First Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-first-quarter-2025-200500635</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-first-quarter-2025-200500635</guid>
<pubDate>Wed, 14 May 2025 20:05:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the current year. Because the spin-off was accounted for a</description>
</item>
<item>
<title>Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-biosciences-announces-departure-cso-200500658</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-biosciences-announces-departure-cso-200500658</guid>
<pubDate>Tue, 01 Apr 2025 20:05:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively.</description>
</item>
<item>
<title>Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results</title>
<link>https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-fourth-quarter-fiscal-200500270</link>
<guid isPermaLink="true">https://6ix.com/company/inhibrx-inc/news/inhibrx-reports-fourth-quarter-fiscal-200500270</guid>
<pubDate>Mon, 17 Mar 2025 20:05:00 GMT</pubDate>
<description>Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A. (the "Acquirer") and the Former Parent's concurrent spin-off of the Inhibrx business in May 2024, the biopharmaceutical company now has two programs in ongoing clinical trials, with data readouts for each expected within the next 12 months. Because</description>
</item>
</channel>
</rss>